

# Developing a Melanoma Clinical Trial Accrual Task Force

Katherine Senter, MPH<sup>1</sup>; Christopher Gantz, MBA, DBA<sup>2</sup>; Nicole Hartman, MPH<sup>1</sup>; Rino Seedor, MD<sup>1</sup> <sup>1</sup>Sidney Kimmel Cancer Center - Jefferson Health, <sup>2</sup>Takeda Pharmaceuticals

### Background **Solutions and Methods Development of patient clinical trial tear pads** The Cancer Center • Sidney Kimmel Cancer Center – Jefferson Health in downtown Philadelphia, PA • NCI-Designated • National referral center for ocular melanoma patients • 1<sup>st</sup> therapy in metastatic setting FDA-approved in 2022 • Clinical trials often the only therapeutic option for patients Newly diagnosed with metastatic or Contact • Historically lower accrual on cutaneous melanoma Katherine Senter, MPH Katherine.Senter@jefferson.edu Office: (215) 503-7488 unresectable melanoma? clinical trials 1015 Walnut Street Suite 1024 Philadelphia, PA 19107 The Team Call the Jefferson Clinical Trials Office **Clinical Trials Finder** JeffersonHealth.org. ClinicalTrials to learn more about clinical trial • Physician lead – medical oncologist • Representatives from Cancer Clinical Research options today. Operations, Clinical Research Outreach and Engagement, and Medical Oncology Outpatient Clinic **Jefferson Health** Sidney Kimmel Cancer Center teams The Task Force • Virtual biweekly or monthly meetings • Development of deliverables between meetings **Internal and external referring provider list** • Meetings with website, electronic health record (EHR), **Quarterly provider newsletter** and marketing teams as needed Sidney Kimmel Cancer Cente Active & Upc Jefferson Health. **Clinical Tri** Goals **Melanoma Medical Oncology at Sidney Kimmel Cancer Center** 11111111 **Clinical Trial Recruitment Newsletter** Dear Colleagues Velcome to our first clinical trial recruitment newsletter! We hope this newsletter will be helpful for you i Brainstorm etting to know our team and learning about our available clinical trials. Increase patient and First, we would like to formally introduce ourselves. We are the melanoma medical oncology team at Sidney Kimmel Cancer Center of Jefferson Health. Led by three medical oncologists – Dr. Takami Sate opportunities across )r. Marlana Orloff, and Dr. Rino Seedor – we work closely with our dermatology and surgical colleagu provider engagement o treat melanoma at all stages. We treat skin melanoma as well as more rare melanomas such as veal/eve melanoma, mucosal melanoma, and acral melanoma. Our multidisciplinary Metastatic Uvea recruitment and felanoma Program is one of only a few across the country around clinical trials Adjuvant mmunotherapy and targeted therapy have had a tremendous impact on the lives of our melanoma enrollment process patients. However, as you know, they do not work for everyone. Here at Jefferson, we are committed ooking for additional treatment options for our patients and are proud to be able to offer promising clinic rials. Please see the next page for a list of our current clinical trials. For additional information please visit https://www.ieffersonhealth.org/clinical-spec cal-trials or email our resea NCT0560829; Upcoming Spring 2023 team at CTO-Melanoma-Research@iefferson.edu Aetastatic 1st Line We hope to send a quarterly update newsletter with our current clinical trials. If you would like to op


**Execute strategies that** attract more melanoma patients to cancer center for clinical trials

**Ensure smooth** screening and enrollment process

**Monitor impact of** task force on protocol accrual



**Prescreening and screening training for trial staff Disease-specific overviews for clinical trial screeners** 



New patient workflow for prospective trial patients EHR prescreening for 1<sup>st</sup> line metastatic melanoma patients

## **Provider Newsletter Distribution**

- **28** opened (**45.9%** open rate compared to 39.1% average) Clicks per unique opens: 10.7%

CS 22-1381

# **Lessons Learned and Future Directions**



outcomes

**Jefferson Clinical Trial Finder Website:** https://www.jeffersonhealth.org/clinicalspecialties/cancer/clinical-trials **Jefferson Melanoma Program:** https://www.jeffersonhealth.org/conditions-andtreatments/melanoma

## **Key Outcomes**

### **EHR Prescreening**

• **197** patients screened Jan 2023-present on single protocol **53** potential patients forwarded to trial team for review • **1** patient enrolled on protocol to date, internal referral • Many "new" diagnoses added in EHR are historical Often potential patients have already treatment plan in

place before trial team notified of eligibility

**61** successful deliveries

### **Current Pre and Post Task Force Yield**

**24** trial patients enrolled in 8.5 months prior to task force development; **24** patients enrolled in 8.5 months post

llaboration is key!	<ul> <li>Dedicated trial recruitment service alleviates burden on disease group</li> <li>Expansion of existing marketing, EHR, and web services</li> </ul>
Sponsor- Suggested	<ul> <li>Patient and provider outreach require significant initial time investment for potentially low yield</li> </ul>
strategies may not	<ul> <li>However, once infrastructure in place, may be scalable; e.g., screen for multiple studies simultaneously</li> </ul>
yield	<ul> <li>Also, task force facilitates Sponsor recruitment discussion during site selection and start-up</li> </ul>
	<ul> <li>Collaboration with pathology may be more effective to</li> </ul>

**Protocol selection and slot availability tailored to clinic patient** population still drive accrual outcomes

capture new diagnoses than EHR problem list

## Resources